Diagnostic and Prognostic Values of Soluble Suppression of Tumorigenicity-2 Measurements in the Treatment Assessment of Adult Patients with Congenital Heart Disease and Cardiac Failure

AUTHORS

Zahra Khajali ORCID 1 , Ata Firouzi ORCID 1 , Maedeh Arabian ORCID 1 , Nasim Naderi ORCID 1 , Majid Maleki ORCID 1 , Sedigheh Saedi ORCID 1 , Maryam Aliramezany ORCID 2 , *

1 Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran

2 Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, IR Iran

How to Cite: Khajali Z, Firouzi A , Arabian M, Naderi N, Maleki M , et al. Diagnostic and Prognostic Values of Soluble Suppression of Tumorigenicity-2 Measurements in the Treatment Assessment of Adult Patients with Congenital Heart Disease and Cardiac Failure, Int Cardio Res J. 2020 ; 14(4):e109763.

ARTICLE INFORMATION

International Cardiovascular Research Journal: 14 (4); e109763
Published Online: December 15, 2020
Article Type: Research Article
Received: September 25, 2020
Accepted: December 07, 2020
READ FULL TEXT

Abstract

Background: The standard heart failure treatment in adult patients with Congenital
Heart Disease (CHD) is a challenging issue. Biomarkers, such as N-Terminal pro-
B-type Natriuretic Peptide (NT-proBNP), have been used, but soluble Suppression of
Tumorigenicity-2 (sST2) has been able to bring prognostic value in patients with acute
and chronic left heart failure.
Objectives: The present study sought to evaluate the predictive value of sST2 and NTproBNP
measurements in the assessment of the efficacy of treatment of adult patients
with symptomatic CHD.
Methods: This case series was conducted using a before/after design on 80 consecutive
adult patients with CHD who had never received treatment for symptomatic heart failure
(New York Heart Association functional classes II, III). sST2 levels were measured before
and six months after the standard drug regimen of cardiac dysfunction according to
the American guidelines in order to assess the efficacy of the standard treatment on
sST2. Cardiac function was assessed via echocardiography and functional capacity via
the 6-Minute Walk Test (6MWT) and direct inquiry from the patients before and six
months after the treatment. The data were entered into the SPSS 22 software and were
analyzed using paired t-test, Wilcoxon, and chi-square test.
Results: The mean age of the patients was 32 years. At the six-month follow-up, functional
capacity showed a significant improvement based on the mean 6MWT compared to
the pre-treatment state (P < 0.001). In addition, the standard treatment significantly
decreased the sST2 level compared to the pre-treatment value (P < 0.001).
Conclusions: The measurement of biomarkers could help assess the efficacy of the
treatment of adult patients with CHD and symptomatic heart failure.

Fulltext

 

 

The full-text is available in pdf.

 

 

 

 

References

  • 1.

    The references are available in pdf.

  • © 2020, Shiraz University of Medical Sciences.
    COMMENTS

    LEAVE A COMMENT HERE: